Show simple item record

dc.contributor.authorShireman, Theresa I.
dc.contributor.authorHall, Jean P.
dc.contributor.authorRigler, Sally K.
dc.contributor.authorMoore, Janice M.
dc.date.accessioned2010-12-14T18:55:25Z
dc.date.available2010-12-14T18:55:25Z
dc.date.issued2007
dc.identifier.citationShireman, T.I., Hall, Jean, P., Rigler, S.K., & Moore, J.M. (2007). Medicaid’s expenditures for newer pharmacotherapies for adults with disabilities. Health Care Financing Review, 28(4), 31-41.
dc.identifier.urihttp://hdl.handle.net/1808/6903
dc.description.abstractMedicaid's drug expenditures have grown at double-digit inflation rates since 2000. These prescription drug costs are important contributors to increasing health care costs for disabled persons. In spite of this knowledge, little has been reported about specific patterns of medication use among disabled enrollees. We analyzed Kansas Medicaid data to describe trend in medication use patterns across 3 years among disabled beneficiaries. The marked shifts toward newer medications and disproportionate contributions of newer, more expensive medications to overall prescription costs for antipsychotics, antidepressants, anticonvulsants, antiulcer medications, anti-inflammatory agents, and opioids have implications for both policy and practice.
dc.language.isoen_US
dc.publisherHealth Care Financing Review
dc.subjectMedicaid
dc.subjectAdults With Disabilities
dc.subjectExpenditures
dc.titleMedicaid’s expenditures for newer pharmacotherapies for adults with disabilities
dc.typeArticle
kusw.kuauthorHall, Jean P.
kusw.kudepartmentDivision of Adult Studies
kusw.oastatusfullparticipation
dc.identifier.orcidhttps://orcid.org/0000-0001-7236-1807 https://orcid.org/0000-0001-6846-8783
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record